RSNA: Early Post-Bevacizumab MRI Predicts Overall Survival in Glioblastoma
Magnetic resonance imaging (MRI) is “highly” predictive of OS rates after bevacizumab-based VEGF blockade chemotherapy for glioblastoma multiforme.
Diagnosis & Disease Information
Avastin Plus Radiation, Chemotherapy Improves Progression-Free Survival in Newly Diagnosed Glioblastoma
Genentech, a member of the Roche Group, announced results from the Phase 3 AVAglio study; the study evaluated Avastin (bevacizumab) in combination with radiation and temozolomide (Temodar; Merck) chemotherapy in patients with newly diagnosed glioblastoma.
Survival Data Announced for Rindopepimut in Glioblastoma
Celldex Therapeutics announced three-year survival data from the Phase 2 rindopepimut clinical program in EGFRvIII-positive glioblastoma—a more aggressive form of glioblastoma typically associated with reduced long-term survival in comparison to the glioblastoma population as a whole.
Orphan Drug Designation for Opaxio for Malignant Brain Cancer
Cell Therapeutics announced that Opaxio (paclitaxel poliglumex) has been granted orphan drug designation by the FDA for the treatment of glioblastoma multiforme (GBM), a malignant brain cancer.
Poorer Survival for Patients with Multifocal Glioblastoma at Diagnosis
Glioblastoma patients presenting with more than one tumor have significantly shorter survival times than those with lone tumors.
Glioma Vaccine Prolongs Survival
A vaccine against targeted antigens prolongs survival in glioblastoma patients, according to a team of researchers.
Modified Tumor Suppressor in Glioblastoma Shortens Survival, Increases Drug Resistance
Modification of a tumor suppressor protein in glioblastomas leads to shortened survival times and drug resistance.
Reinvigorated Interest in Immunotherapy Heralds New Era for Cancer Vaccines
Recent achievements in the field of cancer immunotherapy have increased interest in cancer vaccines.
Increased Retinoblastoma Risk Found in Children of U.S. Born Latinas
Children of U.S.-born Latinas have a high risk of developing retinoblastoma.
Presence of Allergy Biomarker Decreases Risk of Brain Cancer
When the interval between testing positive for total IgE and diagnosis of glioma was at least 20 years, there was a decreased risk of developing the disease.
- Loading...
Loading...
Loading... 
Loading...